The Latest News from Health GAP
Dedicated to eliminating barriers to global access to affordable life-sustaining medications for people living with HIV/AIDS.
Gilead’s Hepatitis C Medicines License
Troubling Territorial Exclusions, Illusory Exceptions, and Tiered Pricing Policy Fracture Global Access
by Professor Brook K. Baker, Northeastern U. School of Law, Senior Policy Analyst Health GAP
Trade law expert Brook Baker analyzes Gilead's Hepatitis C medicines license and its impacts on access around the world.
"Gilead has just announced and released the text of its license on two direct-acting oral antivirals (DAAs) used to treat hepatitis C virus (HCV) infections, sofosbuvir (Sovaldi®) and ledipasvir. The License allows seven Indian generic companies – Cadila Healthcare Ltd., Cipla Ltd., Hetero Labs Ltd., Mylan Laboratories Ltd., Ranbaxy Laboratories Ltd., Sequent Scientific Ltd. and Strides Arcolab Ltd. – to manufacture, distribute and sell the individual products and a combination pill of the two products in a subset of 91 low- and middle-income countries (see list attached)."
Ugandan and International groups call for urgent action by the World Bank to fight discrimination in Uganda's health sector
Ugandan and International groups today released a letter to World Bank Executive Director Dr. Jim Kim calling for urgent action to address pervasive discrimination in the health sector, especially for LGBTI communities. The World Bank suspended a $90 million loan to Uganda's health sector when the President signed the Anti Homosexuality Act into law. While this anti gay law was recently overturned, discrimination is still alive and well, and is undermining access to lifesaving health services. The organizations are calling for corrective action by the Government of Uganda--before the loan is restarted.
New Health GAP analysis published on emboldening the fight to win the end of AIDS--and combatting austerity